Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 13/20 | 0.71 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574449 | 1.00 | GRIA4 (0.71) | GRIA4GRIA2FFAR1CA12CA1 | |
| SCHEMBL4605907 | 0.84 | GRIA4 (1.00) | GRIA4GRIA2KCNH2 | |
| SCHEMBL4606344 | 0.84 | GRIA4 (1.00) | GRIA4GRIA2KCNH2 | |
| SCHEMBL6573061 | 0.84 | GRIA4 (1.00) | GRIA4GRIA2KCNH2 | |
| SCHEMBL4608018 | 0.84 | GRIA4 (1.00) | GRIA4GRIA2KCNH2 | |
| SCHEMBL6574456 | 0.83 | GRIA4 (0.47) | GRIA4GRIA2FFAR1CA12CA1 | |
| SCHEMBL4608046 | 0.82 | GRIA4 (0.84) | GRIA4GRIA2KCNH2 | |
| SCHEMBL4605860 | 0.82 | GRIA4 (0.84) | GRIA4GRIA2KCNH2 | |
| SCHEMBL6761961 | 0.81 | GRIA4 (0.65) | GRIA4GRIA2KCNH2 | |
| SCHEMBL6761960 | 0.81 | GRIA4 (0.65) | GRIA4GRIA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1409452-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002098846-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | GRIA4 9/4885GRIA2 7/4885FFAR1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.